Hvivo

HVO · AIM · Health Care · mcap £41m · 5.8p

hVIVO runs human challenge trials, in which volunteers are deliberately infected with viruses such as flu and RSV in quarantine units to test vaccines and antivirals for pharma and biotech clients. It also offers laboratory services, early-phase clinical units in Germany and bio-storage.

Target	Promise	Said	Status
Today · 17 Oct 2026
2026
2026	CRS German units earnings accretive in 2026	29 Jan 2025	… In progress
	“CRS remains on track to become earnings accretive in 2026.” Also stated 10 Apr 2025 · 22 Jul 2025 · 23 Sep 2025 · 20 Nov 2025 · 15 Apr 2026 How it developed 29 Jan 2025 Said “Acquisition expected to be earnings accretive in 2026” 10 Apr 2025 Said “Integration of the acquisition of two Clinical Research Units from CRS underway, with the units expected to be earnings accretive in 2026” 22 Jul 2025 Said “the Company expects CRS to be earnings accretive in 2026” 23 Sep 2025 Said “CRS remains on track to become profitable in 2026” 20 Nov 2025 Said “CRS remains on track to become earnings accretive in 2026.” 15 Apr 2026 Said “The acquisitions are expected to contribute positively to earnings in the current financial year” Status so far Not yet due.
FY 2026	High single-digit revenue growth in 2026, about £47m	22 Jul 2025	… In progress
	“FY 2026 Group revenue is expected to be approximately £47 million” Also stated 23 Sep 2025 · 29 Jan 2026 · 15 Apr 2026 · 23 Jul 2026 · 15 Sep 2026 How it developed 22 Jul 2025 Said “expects to achieve growth in 2026 and beyond as the macro and sector-specific headwinds abate” 23 Sep 2025 Said “hVIVO expects to achieve high-single digit revenue growth in 2026 on the back of anticipated growth in its newly diversified services” 29 Jan 2026 Said “high single digit revenue growth in 2026” 15 Apr 2026 Said “High single-digit revenue growth expected in 2026, weighted to H2” 23 Jul 2026 Said “The Company expects 2026 full-year revenue to be broadly in line with expectations of high single-digit revenue growth” 15 Sep 2026 Said “FY 2026 Group revenue is expected to be approximately £47 million” Status so far Not yet due.
H2 2026	Report positive adjusted EBITDA in H2 2026	23 Jul 2026	… In progress
	“The Group expects to report positive adjusted EBITDA in H2 2026” Also stated 15 Sep 2026 How it developed 23 Jul 2026 Said “with positive adjusted EBITDA expected in H2 2026” 15 Sep 2026 Said “The Group expects to report positive adjusted EBITDA in H2 2026” Status so far Not yet due.
FY26	CRS Berlin acquisition earnings accretive and positive to revenue and EBITDA in FY26	27 Aug 2026	… In progress
	“Expected to be immediately earnings accretive and contribute positively to both revenue and EBITDA in FY26” Also stated 27 Aug 2026 How it developed 27 Aug 2026 Said “Expected to be immediately earnings accretive and contribute positively to both revenue and EBITDA in FY26” 27 Aug 2026 Said “Expected to be immediately earnings accretive and contribute positively to both revenue and EBITDA in FY26” Status so far Not yet due.
H2 2026	H2 2026 revenue about double H1's £16.3m	15 Sep 2026	… In progress
	“H2 2026 revenue is expected to be approximately double that reported in H1” Status so far Not yet due.